Application of MTA3 in preparation of PD-L1/PD-1 monoclonal antibody tumor immunotherapy medicine

A PD-L1, anti-tumor immune technology, applied in PD-L1/PD-1 monoclonal antibody tumor immunotherapy, biological field, can solve the problems of sexual drug resistance and complex tumor microenvironment

Pending Publication Date: 2022-04-15
XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Since PD-1/PD-L1-related inhibitors have long-lasting anti-tumor effects, especially in some refractory malignant tumors, since 2014, multiple drugs targeting the PD-L1/PD-1 pathway have been successively It has been approved by the FDA for the treatment of a variety of malignant tumors, and its indications are wider than th

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MTA3 in preparation of PD-L1/PD-1 monoclonal antibody tumor immunotherapy medicine
  • Application of MTA3 in preparation of PD-L1/PD-1 monoclonal antibody tumor immunotherapy medicine
  • Application of MTA3 in preparation of PD-L1/PD-1 monoclonal antibody tumor immunotherapy medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] 1. Expression and function analysis of sphingosine kinase in tumor tissues.

[0038] 1.1 Experimental method: The gene transcriptome of 33 types of cancer (including 10205 tumor samples) was obtained from the Cancer Genome Atlas (TCGA) database (http: / / gdac.broadinstitute.org / ) using the FPKM (Fragments Per Kilobase per Million) algorithm data. Use limma1.4.5 to analyze the fold change (Fold change, FC) of genes in tumors and corresponding normal tissues, and the screening threshold is |Log 2 (FC)|>0.58, using the Benjamini-Hochberg (BH) method to correct the P value of the hypothesis test probability. The Spearman correlation coefficient and its significance test were used to analyze the correlation between genes in tumor tissues, and the test level was α=0.05.

[0039] 1.2 Experimental results:

[0040] Gene set variation analysis was performed by comparing tumor and normal tissues of different cancer types in The Cancer Genome Atlas (TCGA) public database, and the...

Embodiment 2

[0066] 1. In vitro study of SPHK1-MTA3 axis regulating the expression level of tumor PD-L1.

[0067] 1.1 Experimental methods: transcriptome sequencing, bioinformatics analysis of TCGA database, gene editing, cell gene intervention, PF543 drug intervention, Western blot, ChIP detection

[0068] The target gene siRNA Oligo sequence is shown in Table 2:

[0069]

[0070]

[0071] The specificity of the primers was judged according to the amplification curve, and the gene primers with poor specificity needed to be redesigned and synthesized. The optimized gene primer sequences are shown in Table 3 below:

[0072]

[0073] 1.2 Experimental results:

[0074] See Figure 4 A, Compared with the control group, among the 4182 significantly down-regulated genes detected in the treatment group, nine candidate transcription factors were identified according to the gene differential expression fold;

[0075] See Figure 4 B, In order to evaluate the reliability of the sequenc...

Embodiment 3

[0093] 1. In vivo study of tumor PD-L1 expression induced by SPHK1 and MTA3.

[0094] 1.1 Group settings:

[0095] CTL+IgG2α isotype control group (control group)

[0096] CTL+PD-1 monoclonal antibody group (PD-1 monoclonal antibody treatment group)

[0097] SPHK1-OE+IgG2α isotype control group (SPHK1 overexpression group)

[0098] SPHK1-OE+PD-1 monoclonal antibody group (SPHK1 overexpression PD-1 monoclonal antibody group)

[0099] MTA3-OE+IgG2α isotype control group (MTA3 overexpression group)

[0100] MTA3-OE+PD-1 monoclonal antibody group (MTA3 overexpression PD-1 monoclonal antibody group)

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of PD-L1/PD-1 monoclonal antibody tumor immunotherapy, and aims to provide a new research and development direction of PD-L1/PD-1 monoclonal antibody tumor immunodetection or immunotherapy adjuvant drugs and a new drug combination mode. Specifically, the invention provides an application of the MTA3 in preparation of a detection kit for a PD-L1/PD-1 monoclonal antibody tumor immunotherapy drug and an application of the combination of the MTA3 and the PD-L1/PD-1 monoclonal antibody drug in preparation of a tumor immunotherapy drug, the tumor is a solid tumor, and the solid tumor is further melanoma.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to the field of PD-L1 / PD-1 monoclonal antibody tumor immunotherapy. Background technique [0002] Skin tumors are the most common type of cancer among all tumors, among which skin malignant melanoma (SKCM) is a highly malignant skin tumor derived from melanocytes. Invasive melanoma accounts for only 1% of skin tumor cases but has a high mortality rate. In the past few decades, the incidence of melanoma has been on the rise in the past few decades, and the mortality rate of skin melanoma has decreased significantly in recent years, mainly due to new treatments and new drugs for metastatic melanoma Improve the survival rate of patients. Surveillance, Epidemiology, and End Results Program (SEER) analysis showed that in 2011, the US Food and Drug Administration (FDA) approved the first cytotoxic T cell-associated protein 4 (Cytotoxic T-cell-associated protein 4). lymphocyte-associated pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/573G01N33/574G01N33/577A61K38/17A61K39/395A61P35/00
Inventor 刘洪陈翔刘宝仪张冠雄
Owner XIANGYA HOSPITAL CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap